009290.KS KSC
Kwang Dong Pharmaceutical Co., Ltd.
1W: +2.5%
1M: +1.9%
3M: +13.3%
YTD: +4.8%
1Y: +7.9%
3Y: +4.4%
5Y: -22.8%
₩6,550.00 ($4.88)
-30.00 (-0.46%)
Weekly Expected Move ±4.4%
₩5976
₩6263
₩6550
₩6837
₩7124
Overview
Chart
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ETF Exposure
Cash Flow Trends
Operating Cash Flow
$82.3B
+777.5% ▲
5Y CAGR: +29.2%
Capital Expenditures
$25.2B
+67.6% ▲
5Y CAGR: +36.6%
Free Cash Flow
$57.1B
+163.5% ▲
5Y CAGR: +26.7%
Dividends Paid
$3.9B
+2.0% ▲
Buybacks
$364M
+91.0% ▲
Net Change in Cash
$41.3B
+6.3% ▲
Cash Flow Composition
Year-over-Year Growth
View Full Cash Flow Statement
| Line Item | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| — Operating Activities — | |||||
| Net Income | $25.5B | $26.7B | $39.4B | $41.8B | $21.0B |
| Depreciation & Amort. | $14.1B | $14.0B | $12.9B | $14.5B | $17.5B |
| Stock-Based Comp. | $18M | $0 | $0 | $0 | $0 |
| Change in Working Capital | -$3.9B | $6.2B | -$69.2B | -$51.3B | $30.0B |
| Other Non-Cash Items | $1.4B | $15.9B | $5.2B | -$17.3B | $13.8B |
| Operating Cash Flow | $54.9B | $62.8B | -$11.7B | -$12.2B | $82.3B |
| — Investing Activities — | |||||
| Capital Expenditures | -$24.4B | -$26.0B | -$34.8B | -$75.7B | -$26.4B |
| Acquisitions (Net) | -$2.3B | -$2.9B | -$21.2B | -$17.1B | $10.9B |
| Investment Purchases | -$505.6B | -$708.6B | -$621.5B | -$102.0B | -$207.3B |
| Investment Sales | $488.9B | $693.6B | $614.2B | $205.3B | $128.3B |
| Other Investing | $464M | $1.2B | -$8.5B | $2.3B | -$8.1B |
| Investing Cash Flow | -$43.0B | -$42.7B | -$71.8B | $12.8B | -$102.6B |
| — Financing Activities — | |||||
| Net Debt Issuance | $22.0B | $5.0B | $69.0B | $46.8B | -$6.1B |
| Stock Repurchased | $86M | $0 | -$6.2B | -$4.1B | -$364M |
| Dividends Paid | -$4.1B | -$4.1B | -$4.1B | -$4.0B | -$3.9B |
| Other Financing | -$1.9B | -$1.5B | -$647M | -$1.9B | -$5.8B |
| Financing Cash Flow | $15.9B | -$628M | $58.0B | $36.8B | $45.5B |
| Net Change in Cash | $29.1B | $19.6B | -$26.2B | $38.8B | $41.3B |
| Cash End of Period | $84.0B | $103.6B | $77.3B | $116.2B | $141.0B |
| Free Cash Flow | $30.5B | $36.8B | -$46.9B | -$89.9B | $57.1B |